Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol

Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol

Confirm central blood pressure reduction effect of Fimasartan, Valsartan and Atenolol and compare correlation with the measured peripheral (central blood pressure, pulse wave velocity, and flow-mediated dilation) and cerebral blood flow factors (transcranial doppler findings, cerebral blood flow volume) in acute ischemic stroke patients with hypertension.

Inclusion Criteria:

• Age ≥ 30 years old
• Acute ischemic stroke patient who has corresponding DWI(diffusion- weighted imaging) lesion correlated with symptom
• after 7days, but within 28days from stroke onset
• Diagnosed with Hypertension
• hypertensive patients who taking anti-hypertensive drugs or SBP≥140mmHg
• Informed consent

Exclusion Criteria:

• Patients with hemorrhagic Stroke
• Patients with severe Stroke - over NIHss(National Institutes of Health stroke scale) 16
• Uncontrolled hypertension (SBP ≥200mmHg)
• Patients with history of allergic reaction to any angiotensin II antagonist
• Liver disease(more than double to normal level, SGOT(serum glutamic-oxaloacetic transaminase ), SGPT(serum glutamic-pyruvic transaminase ), total bilirubin)
• Renal disease(serum creatinine ≥2.0mg/dl)
• Anemia(Hb < 8mg/dl)
• Thrombocytopenia( < 10^3/ml)
• Patients with secondary hypertension
• Childbearing and breast-feeding women
• Otherwise inappropriate patients depending on the investigator's decision